Therefore, in this study, the regulatory role of METTL3 and PSMA3-AS1 in the disease process was verified by bioinformatics combined with in vitro and in vivo experiments, which provided the basis for the development of targeted drugs for FLT3-ITD AML. Here, METTL3 is linked to acute myeloid leukemia.